NCT06345755CompletedPhase 1
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 14 Jul 2025
Brief summary (registry, in English)
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 159 (actual)
- First submitted
- 28 Mar 2024
- Start date
- Apr 2024
- Primary completion date
- Jan 2025
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Diseases
- Polycystic kidney disease
- NCT number
- NCT06345755
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 159
- From Apr 2024 to the primary completion date, Jan 2025
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
Other illness
- Any condition possibly affecting drug absorption
- Other protocol defined Inclusion/Exclusion criteria may apply.
Who the study is looking for
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of greater than (\>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Altasciences Montreal Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| ICON Lenexa Coordinator of this site? Confirm its status | Lenexa | United States | Unknown status |
Related publications
- The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.Clin J Am Soc Nephrol · 2026 · PMID 41348481
This page is information, not medical advice. Discuss any trial with your doctor.